Teva Acquires Worldwide Rights to BXCL501 for $57.5 Million Upfront
Teva completed the asset acquisition, securing worldwide rights to BXCL501. The deal includes up to $67.5 million in potential contingent payments and received U.S. Bankruptcy Court approval.